| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 07/23/2009 | US20090186078 Treatment of triple receptor negative breast cancer |
| 07/23/2009 | US20090186077 Thermo-responsive materials |
| 07/23/2009 | US20090186076 Combined Use of TGF-Beta Signaling Inhibitor and Antitumor Agent |
| 07/23/2009 | US20090186075 Composition |
| 07/23/2009 | US20090186074 Lipid vesicles derived from olive oil fatty acids |
| 07/23/2009 | US20090186073 Design of Delivery Vehicle Based On Rolling Model |
| 07/23/2009 | US20090186072 Operational status for active transdermal medicament patch |
| 07/23/2009 | US20090186071 Clay-based hemostatic agents and devices for the delivery thereof |
| 07/23/2009 | US20090186070 Particle immobilized coating and uses thereof |
| 07/23/2009 | US20090186066 Method for production of chitosan-based films with enhanced cell adhering capacity, resulting product and applications |
| 07/23/2009 | US20090186065 Isolating and purifying cells for therapy |
| 07/23/2009 | US20090186063 Preparation for regeneration of postoperative, post-traumatic bone defects and method for implantation of this preparation |
| 07/23/2009 | US20090186062 Method of Repairing Meniscal Tears |
| 07/23/2009 | US20090186061 Composition Comprising Polymeric, Water-Insoluble, Anionic Particles, Processes and Uses |
| 07/23/2009 | US20090186060 Methods of enhancing radiation effects with metal nanoparticles |
| 07/23/2009 | US20090186059 Devices and methods for elution of nucleic acid delivery complexes |
| 07/23/2009 | US20090186057 Topical Use of Probiotic Bacillus Spores to Prevent or Control Microbial Infections |
| 07/23/2009 | US20090186056 Compositions and methods for preventing infection |
| 07/23/2009 | US20090186035 Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
| 07/23/2009 | US20090185996 Hydroxyethyl starch-containing polypeptide compositions |
| 07/23/2009 | US20090185983 Aqueous medicament preparations for the production of propellant gas-free aerosols |
| 07/23/2009 | US20090185982 Approach to the treatment of compartment syndrome |
| 07/23/2009 | US20090185976 Method for introducing a chemical agent into the systemic circulation |
| 07/23/2009 | US20090184281 doping on lattice level composition engineering, and sintering to produce a product with desirable properties; Tungsten-Doped Tin Oxide; Copper Doped Nickel Zinc Ferrite; semiconductors |
| 07/23/2009 | DE4418115B4 Galenische Formulierungen Pharmaceutical formulations |
| 07/23/2009 | DE102008004893A1 Trägerpellets, Verfahren zu deren Herstellung und deren Verwendung Carrier pellets, processes for their preparation and their use |
| 07/23/2009 | DE102008004571A1 Device to treat particulate biological or pharmacological material, has hot gaseous medium, treatment zone, blower to circulate the medium, separator formed as centrifugal separator with inlet and outlets, and wrapped deflecting element |
| 07/23/2009 | CA2787097A1 Low viscosity liquid polymeric delivery system |
| 07/23/2009 | CA2749611A1 Parenteral formulations of dopamine agonists |
| 07/23/2009 | CA2714286A1 The use of an acetylsalicylic acid salt for treating viral infections |
| 07/23/2009 | CA2713365A1 Stabilized sustained release composition of bupropion hydrochloride and process for preparing the same |
| 07/23/2009 | CA2712527A1 Chitosan gel for dermatological use, production method and use of same |
| 07/23/2009 | CA2712299A1 Method for stabilization of s-nitrosoglutathione and composition prepared by the same |
| 07/23/2009 | CA2712120A1 Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
| 07/23/2009 | CA2711984A1 Powdered protein compositions and methods of making same |
| 07/23/2009 | CA2711073A1 Implantable devices for promoting reendothelialization and methods of use thereof |
| 07/23/2009 | CA2709868A1 Monolithic alginate implants crosslinked in situ |
| 07/23/2009 | CA2709357A1 Mesalazine tablet |
| 07/22/2009 | EP2080804A1 Modified cytokines for use in cancer therapy |
| 07/22/2009 | EP2080771A2 New interferon beta-like molecules |
| 07/22/2009 | EP2080767A1 Composition for introduction of nucleic acid |
| 07/22/2009 | EP2080524A1 Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process |
| 07/22/2009 | EP2080522A1 Thermoreversible immuno-adjuvant emulsion |
| 07/22/2009 | EP2080520A1 Tryptophanyl-tRNA synthetase derived polypeptides useful for the regulation of angiogenesis |
| 07/22/2009 | EP2080515A1 Pharmaceutical formulations containing flavouring substances with improved pharmaceutical properties |
| 07/22/2009 | EP2080514A1 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic |
| 07/22/2009 | EP2080511A2 Active agent delivery systems and methods for protecting and administering active agents |
| 07/22/2009 | EP2080510A1 Method for production of liposome preparation |
| 07/22/2009 | EP2080509A1 Lubricious, non-tacky personal lubricant |
| 07/22/2009 | EP2080508A1 Dry powder formulation comprising an anticholinergic drug |
| 07/22/2009 | EP2080507A1 Pharmaceutical formulations comprising an anticholinergic drug |
| 07/22/2009 | EP2080504A2 Topical composition comprising n-acetylaldosamines or n-acetylamino acids |
| 07/22/2009 | EP2080501A1 Drug solution having reduced dissolved oxygen content, method of producing the same and drug solution containing unit having reduced dissolved oxygen content |
| 07/22/2009 | EP2079529A1 Antimicrobially active composition having a content of bispyridinium alkane (octenidine dihydrochloride) |
| 07/22/2009 | EP2079527A2 Use of deuterium dioxide for treating hyperproliferative skin diseases |
| 07/22/2009 | EP2079474A1 Liposome encapsulated poly-iclc method to prophylactically treat an avian influenza viral infection |
| 07/22/2009 | EP2079473A1 Dermatological composition containing avermictin nanocapsules, method for preparing the same and uses thereof |
| 07/22/2009 | EP2079468A1 Oral care compositions containing combinations of anti-bacterial and host-response modulating agents |
| 07/22/2009 | EP2079458A2 Transdermal therapeutic system with two-phase releasing profile |
| 07/22/2009 | EP2079457A2 A method of administering a film product containing a drug |
| 07/22/2009 | EP2079456A2 Pharmaceutical cyclosporin compositions |
| 07/22/2009 | EP2079455A1 Pharmaceutical composition comprising a dihydrobenzofuranyl isoindoline and a lipophilic component |
| 07/22/2009 | EP2079454A2 Sugar coatings and methods therefor |
| 07/22/2009 | EP2079453A1 Robust sustained release formulations |
| 07/22/2009 | EP2079452A1 Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers |
| 07/22/2009 | EP2079451A1 Combined preparation for the treatment of cardiovascular diseases based on chronotherapy theory |
| 07/22/2009 | EP2079450A2 Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions |
| 07/22/2009 | EP2079449A2 Phenylalkylamino carbamate compositions |
| 07/22/2009 | EP2079448A2 Improved release of statins in the intestine |
| 07/22/2009 | EP2079447A1 Pharmaceutical solid dosage forms comprising compounds micro-embedded in ionic water-insoluble polymers |
| 07/22/2009 | EP2079446A1 Paliperidone sustained release formulation |
| 07/22/2009 | EP2079445A2 Stable digestive enzyme compositions |
| 07/22/2009 | EP2079444A2 Particles for cell targeting |
| 07/22/2009 | EP2079443A2 Dual action, inhaled formulations providing both an immediate and sustained release profile |
| 07/22/2009 | EP2079442A2 Use of glycerophospholipids for joint lubrication |
| 07/22/2009 | EP2079441A1 Topical antibiotic composition for the prevention of lyme disease |
| 07/22/2009 | EP2079440A2 Two-compartment skincare products comprising ivermectin, and uses thereof |
| 07/22/2009 | EP2079439A1 Methods and ophthalmic devices used in the treatment of ocular allergies |
| 07/22/2009 | EP2079380A1 Method of treating cancer comprising introduction of heat and delivery of liposome containing an active agent or thermo-activated drug, gene or virus to tissue |
| 07/22/2009 | EP2079313A2 Antimicrobial and antiviral compounds and methods for their use |
| 07/22/2009 | EP2012768A4 Oral patch with salt of glycyrrhetinic acid water soluble at human mouth temperatures |
| 07/22/2009 | EP2005968A9 Nanocomposite particle |
| 07/22/2009 | EP1998784B1 Medicaments and methods comprising a compound that promotes oestrogenic activity for wound healing |
| 07/22/2009 | EP1803447B1 Pharmaceutical composition for the sustained release of hydralazine and use thereof as a support for cancer treatment |
| 07/22/2009 | EP1740235B1 Coating compositions for bioactive agents |
| 07/22/2009 | EP1694292B1 Therapeutic foam comprising a sclerosing solution and a low quanitiy of gaseous nitrogen |
| 07/22/2009 | EP1663395B1 Multi-system therapy for diabetes, the metabolic syndrome and obesity comprising a hypoglycemic agent |
| 07/22/2009 | EP1499290B1 Warming and nonirritating lubricant compositions |
| 07/22/2009 | EP1458413B1 Pharmaceutical compositions based on azetidine derivatives |
| 07/22/2009 | EP1397050B1 Chewing gum to control malodorous breath |
| 07/22/2009 | EP1392337B2 Pharmaceutical formulation consisting of a plant dry extract with a calcium coating |
| 07/22/2009 | EP1392241B1 System for osmotic delivery of pharmaceutically active agents |
| 07/22/2009 | EP1379224B1 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
| 07/22/2009 | EP1343518B1 Stabilized interferon compositions |
| 07/22/2009 | EP1282447B1 Stable polymeric micelle-type drug composition and method for the preparation thereof |
| 07/22/2009 | EP1255563B1 Composition of antigen and glycolipid adjuvant sublingual administration |
| 07/22/2009 | EP1251877A4 Site specific binding system, nuclear imaging compositions and methods |
| 07/22/2009 | EP1244455B1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 07/22/2009 | EP1109563A4 End modified thermal responsive hydrogels |
| 07/22/2009 | EP1027033B1 High efficiency encapsulation of nucleic acids in lipid vesicles |